Core Viewpoint - Kangfeng Biotech-B (06922) has received approval from the National Medical Products Administration for its anti-reflux system, enhancing the diversity of its product portfolio [1] Group 1: Product Approval - The anti-reflux system consists of an implanted anti-reflux device and esophageal measurement tools, which are set to be available by December 15, 2025 [1] - The approval signifies a significant milestone for the company, indicating progress in its product development and regulatory compliance [1] Group 2: Product Functionality - The anti-reflux system is a self-developed surgical instrument designed for use in magnetic enhancement surgery of the lower esophageal sphincter to treat gastroesophageal reflux disease [1] - The system works by implanting a device in the functional area of the lower esophageal sphincter, where magnetic beads create an attractive force to enhance the tension of the sphincter, thereby restoring its anti-reflux function [1]
康沣生物-B(06922)：抗胃食管反流系统获得国家药监局批文